Merck's Keytruda could offer cure for melanoma, study reveals

18 May 2016

Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) improves long-term survival rates in newly diagnosed and previously treated patients with advanced melanoma and might even offer a complete cure, according to the results of an early-stage study.

Long-term follow up from a large Phase Ib trial (KEYNOTE -001) revealed that 40% of patients were alive three years after starting pembrolizumab. The median overall survival was 24.4 months. Of note, 15% of patients in the study experienced complete remission according to immune-related response criteria, and 89% remain in remission.

This is in contrast to a median overall survival of less than one year before Bristol-Myers Squibb’s (NYSE: BMY) immunotherapy drug ipilimumab (Yervoy) was first approved by the US Food and Drug Association (FDA) as the first drug to extend survival in patients with advanced melanoma in 2011.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK